Suppr超能文献

苯妥英与氟尿嘧啶的相互作用。

Phenytoin and fluorouracil interaction.

作者信息

Gilbar P J, Brodribb T R

机构信息

Division of Medicine, Toowoomba Health Services, Australia.

出版信息

Ann Pharmacother. 2001 Nov;35(11):1367-70. doi: 10.1345/aph.1A051.

Abstract

OBJECTIVE

To report a probable drug interaction between phenytoin and fluorouracil.

CASE REPORT

A 66-year-old white man started adjuvant chemotherapy for colon cancer with weekly bolus injections of fluorouracil and leucovorin calcium. He had been taking phenytoin 300 mg/d for epilepsy for more than four years. Eleven weeks later, the patient was reported to be unsteady on his feet and had fallen several times. The serum phenytoin concentration at that time was 36 microg/mL. The phenytoin dosage was decreased and the symptoms resolved. Phenytoin concentrations were monitored and the dosages were adjusted accordingly throughout the remaining 15 weeks of treatment with fluorouracil. After completion of chemotherapy, the phenytoin dose was gradually increased to the original dose with no signs of toxicity.

DISCUSSION

Phenytoin is principally metabolized by CYP2C9. Inhibition of that isoenzyme by fluorouracil, and possible interference with its synthesis, appears to be the most likely cause of this interaction. The reduction in saturating substrate concentration of phenytoin was reduced as a result of this interaction, thus causing decreased clearance and increased serum concentrations. No previous interaction between phenytoin and fluorouracil has been reported. Both phenytoin and warfarin are metabolized by CYP269 and therefore exhibit the same spectrum of interactions when that isoenzyme is inhibited. Interactions have been reported with concurrent administration of warfarin and fluorouracil.

CONCLUSIONS

The nature and extent of this phenytoin-fluorouracil interaction should be elucidated by in vitro investigations and a prospective study. Until then, clinicians should be aware of this potentially serious drug interaction and monitor patients closely for phenytoin toxicity.

摘要

目的

报告苯妥英钠与氟尿嘧啶之间可能存在的药物相互作用。

病例报告

一名66岁白人男性开始接受结肠癌辅助化疗,每周静脉推注氟尿嘧啶和亚叶酸钙。他因癫痫服用苯妥英钠300mg/d已超过四年。十一周后,据报告该患者步态不稳且跌倒过几次。当时血清苯妥英钠浓度为36μg/mL。降低了苯妥英钠剂量,症状得以缓解。在氟尿嘧啶治疗的剩余15周期间,监测苯妥英钠浓度并相应调整剂量。化疗结束后,苯妥英钠剂量逐渐增加至原剂量,未出现毒性迹象。

讨论

苯妥英钠主要通过CYP2C9代谢。氟尿嘧啶对该同工酶的抑制作用以及可能对其合成的干扰,似乎是这种相互作用最可能的原因。这种相互作用导致苯妥英钠饱和底物浓度降低,从而使清除率下降,血清浓度升高。此前未见苯妥英钠与氟尿嘧啶之间相互作用的报道。苯妥英钠和华法林均由CYP2C9代谢,因此当该同工酶受到抑制时,它们表现出相同的相互作用谱。已有华法林与氟尿嘧啶同时给药时相互作用的报道。

结论

这种苯妥英钠 - 氟尿嘧啶相互作用的性质和程度应通过体外研究和前瞻性研究加以阐明。在此之前,临床医生应意识到这种潜在的严重药物相互作用,并密切监测患者的苯妥英钠毒性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验